Peptide Bicyclic Scaffold Engineering: Advances in Constrained Peptide Design

What Are Bicyclic Peptides?

Bicyclic peptides are peptide chains that are locked into a rigid, double-ring structure. Two separate bonds constrain the molecule, creating a three-dimensional shape that linear peptides cannot achieve.

This rigid structure is not just an interesting chemistry trick. It fundamentally changes how the peptide behaves in the body and how it interacts with its target.

Christian Heinis, Professor of Chemical Biology at EPFL, described them in the Annual Review of Biochemistry (2021): "The bicyclic peptide format occupies a sweet spot between small molecules and biologics, combining the tissue penetration of one with the selectivity of the other."

Why Scaffold Engineering Matters

Linear peptides are flexible and can fold into many different shapes. That flexibility means they may not always present their binding surface in the optimal way.

Bicyclic scaffolds force the peptide into one defined shape. This "pre-organized" binding conformation increases target affinity and selectivity dramatically.

Bicyclic peptide technology was pioneered in part by Christian Heinis at EPFL in Switzerland. His lab developed the phage display platform that allowed researchers to screen billions of bicyclic peptide variants for binding activity against any target.

A single phage display screen can evaluate over 10 billion unique bicyclic peptide sequences against a therapeutic target in just a few weeks.

How Bicyclic Scaffolds Are Created

The most common method for creating a bicyclic peptide is called chemical bicyclization. A linear peptide containing three cysteine residues is reacted with a trifunctional linker molecule.

The linker connects all three cysteine side chains at once, forming two rings simultaneously. The result is a compact, rigid structure with well-defined geometry.

Other methods include:

• Disulfide bridge cyclization (natural or engineered)
• Amide bond cyclization between non-adjacent residues
• Thioether ligation
• Click chemistry crosslinking
• Metal coordination cyclization

Each method produces a different scaffold geometry. The choice depends on the target, the desired pharmacology, and the synthesis capabilities of the team.

Key Advantages Over Linear and Monocyclic Peptides

Bicyclic peptides outperform simpler peptide formats in several critical areas.

Property	Linear Peptide	Monocyclic Peptide	Bicyclic Peptide
Protease stability	Low	Moderate	High
Target binding affinity	Variable	Good	Excellent
Receptor selectivity	Variable	Moderate	High
Oral bioavailability	Very low	Low	Low to moderate
Plasma half-life	Short	Moderate	Long
Synthetic complexity	Low	Moderate	High

The trade-off is synthesis complexity. Bicyclic peptides require more sophisticated chemistry and quality control than their simpler counterparts.

Protease Resistance: A Key Property

One of the biggest challenges for peptide drugs is that enzymes in the blood break them down quickly. Linear peptides are especially vulnerable because proteases can access the peptide backbone easily.

The rigid, compact structure of a bicyclic peptide makes it much harder for proteases to grab and cleave the backbone. Studies have shown bicyclic peptides can have plasma half-lives ten to one hundred times longer than equivalent linear peptides.

This extended stability reduces the dosing frequency needed for therapeutic effect. Less frequent dosing means better patient compliance and lower treatment burden.

Targeting Protein-Protein Interactions

Protein-protein interactions (PPIs) are targets that have long been considered "undruggable." Small molecules are too small to block the large flat surfaces where proteins interact with each other.

Bicyclic peptides are large enough to cover these interaction surfaces while still being small enough to penetrate tissues. This puts a whole new class of disease-relevant targets within reach.

Cancer, inflammatory diseases, and infectious diseases all have important PPI targets. Bicyclic peptides are being developed as inhibitors of PPIs in all three areas.

It is estimated that the human proteome contains over 650,000 protein-protein interactions, but fewer than 2% are currently targeted by approved drugs. Bicyclic peptides are one of the most promising approaches to closing this gap.

When building a bicyclic peptide program, prioritize hiring chemists with hands-on trifunctional linker experience, since the cyclization step is where most synthesis failures occur and where specialized skill matters most.

Phage Display Screening for Bicyclic Peptides

Phage display is the most powerful tool for finding bicyclic peptides with activity against a target of interest. Billions of different bicyclic peptide sequences can be screened in a single experiment.

The process works by displaying bicyclic peptide variants on the surface of bacteriophage (viruses that infect bacteria). The phage are then mixed with the target protein. Phage that display binding peptides stick to the target and are recovered.

Multiple rounds of selection produce highly potent, highly selective bicyclic peptide binders. The winning sequences are then identified by DNA sequencing.

This platform has been used to find bicyclic peptide leads against cancer targets, viral proteins, bacterial virulence factors, and many others.

Optimizing Bicyclic Scaffolds for Drug-Like Properties

Finding a bicyclic peptide that binds its target is just the first step. The molecule must also have appropriate pharmacokinetics and be manufacturable at scale.

Key optimization parameters include:

Parameter	Optimization Strategy
Plasma stability	Non-natural amino acids, N-methylation
Cell penetration	Cationic residues, lipid conjugation
Renal clearance	PEGylation, serum albumin binding moieties
Solubility	Charged residues, hydrophilic linkers
Synthesis yield	Simplified linker chemistry, protecting group strategy

Structure-activity relationship (SAR) studies guide optimization. Each change to the scaffold is tested to understand how it affects both binding activity and pharmacokinetic properties.

Clinical and Pipeline Examples

Bicyclic peptide drugs are advancing through clinical development at a growing pace. Bicycle Therapeutics, a UK-based company, has been a leader in this space.

Their BT8009 compound, targeting Nectin-4, entered clinical trials for bladder cancer. It is designed to deliver a cytotoxic payload specifically to tumor cells expressing the target.

Several other companies are pursuing bicyclic peptides for oncology, infectious disease, and pain management. The pipeline is young but growing rapidly.

Learn how to find the right peptide research talent to support your bicyclic program

According to research published on PubMed, the number of bicyclic peptide-related publications has grown by over 300% in the past decade, reflecting intense global interest in the technology.

Manufacturing Considerations for Bicyclic Peptides

Making bicyclic peptides at scale presents unique challenges. The cyclization chemistry must work reliably across different batch sizes.

Solid-phase peptide synthesis (SPPS) is the standard method for making the linear precursor. The cyclization step is then performed in solution, typically using an excess of the trifunctional linker.

Purification by HPLC is used to separate the correctly folded bicyclic product from any linear or monocyclic side products. Analytical methods must be validated to confirm the structure and purity of each batch.

Explore how peptide AI tools are accelerating bicyclic scaffold design

Where the Field Is Heading

The field is moving toward more complex and functional scaffolds. Researchers are exploring tricyclic peptides, peptide-small molecule hybrids, and scaffolds with built-in degradation mechanisms.

AI and machine learning are beginning to play a role in scaffold design. Generative models can propose novel bicyclic sequences with predicted binding properties, reducing the need for exhaustive experimental screening.

The combination of phage display, AI-guided optimization, and improved synthesis technology is creating a powerful platform for drug discovery.

FAQ: Peptide Bicyclic Scaffold Engineering

What makes a bicyclic peptide different from a regular cyclic peptide? A regular cyclic peptide has one ring formed by a single bond between the peptide ends. A bicyclic peptide has two rings, created by two separate crosslinks, which creates a much more rigid and constrained structure.

Why are bicyclic peptides more stable than linear peptides? The rigid double-ring structure prevents proteases from accessing the peptide backbone efficiently. This resistance to enzymatic degradation dramatically extends the half-life in biological fluids.

Can bicyclic peptides be taken orally? Most bicyclic peptides are not orally bioavailable, but certain scaffold designs have shown improved gut absorption. This is an active area of research. Most current applications use injection or local delivery.

What is phage display and how is it used in bicyclic peptide discovery? Phage display is a technique where billions of peptide variants are displayed on the surface of viruses. The collection is screened against a target protein to find the peptides that bind with the highest affinity.

How large is the typical bicyclic peptide molecule? Bicyclic peptides are typically six to twenty amino acids in length, giving molecular weights of roughly 700 to 2500 daltons. This places them between small molecules and biologics in size.

What diseases are bicyclic peptides being developed for? The biggest focus areas are oncology (especially targeted drug delivery), infectious diseases (viral and bacterial targets), and inflammatory conditions with PPI targets.

How long does it take to develop a bicyclic peptide drug candidate? From initial screening through lead optimization to candidate nomination typically takes two to four years. The subsequent clinical development follows standard timelines of seven to ten years.